1.DHEA ( dehydroepiandrosterone ).
Journal of Korean Society of Endocrinology 1997;12(1):1-7
No abstract available.
Dehydroepiandrosterone*
2.The medical treatment of osteoporosis.
Korean Journal of Medicine 2010;79(3):250-253
No abstract available.
Osteoporosis
3.Role of Wnts, LRPs, and sFRPs in Bone.
Journal of Korean Society of Endocrinology 2003;18(1):1-4
No abstract available.
4.Liver in Systemic Lupus Erythematous: Clinicopathological analysis of 8 cases.
Young Nyun PARK ; Chan Il PARK ; Yoon Sok CHUNG ; Si Young SONG ; Chein Soo HONG
Korean Journal of Pathology 1992;26(5):445-450
Hepatic changes in eight cases of systemic lupus erythematosus(SLE), were studied to evaluate the nature of hepatic injury of SLE and its relation to lupoid hepatitis. Common histologic changes of the liver in SLE included intralobular necro-inflammatory activities, fatty change, canalicular bile stasis and mild perivenular and Disse space fibrosis. The fatty change and intralobular fibrosis were thought not to be due to SLE itself but associated with steroid administration or chronic alcoholic consumption. The necro-inflammatory changes were usually mild and features of chronic active hepatitis with periportal destruction occured in one case. Symptoms related to the involvement of many other organs than the liver appeared much frequently in patients with SLE than lupoid hepatitis, suggesting that the SLE involving liver and the lupoid hepatitis are different diseases.
5.Apoptosis of bone cells and bisphosphonates.
Korean Journal of Medicine 1999;57(4):472-476
No abstract available.
Apoptosis*
;
Diphosphonates*
6.Clinical usefulness of urinary growth hormone measurements in adults.
Yoon Sok CHUNG ; Hyun Chul LEE ; Kap Bum HUH ; Duk Hi KIM ; Myung Hee LEE
Journal of Korean Society of Endocrinology 1993;8(4):398-403
No abstract available.
Adult*
;
Growth Hormone*
;
Humans
7.Current and Upcoming Treatments for Osteoporosis.
Journal of Rheumatic Diseases 2012;19(1):4-10
Osteoporosis is a common senile disease that results in fragility fractures. With an ageing population, the medical and socioeconomic effect of osteoporosis, particularly postmenopausal osteoporosis, will increase further. Currently, good anti-fracture data supports many available anti-resorptive and anabolic drugs including bisphosphonates, selective estrogen receptor modulators, and recombinant human parathyroid hormones. Calcium and vitamin D are also essential treatments for the prevention and treatment of osteoporosis. Although, bisphosphonate is the cornerstone of osteoporosis treatment and is considered as the first line of therapy, their duration of therapy and long-term safety is under question. Novel agents, particularly denosumab, inhibitors of cathepsin K, andanabolic agents that act on Wnt signaling, will increase the therapeutic options for clinicians in the coming years.
Antibodies, Monoclonal, Humanized
;
Calcium
;
Cathepsin K
;
Diphosphonates
;
Female
;
Humans
;
Osteoporosis
;
Osteoporosis, Postmenopausal
;
Selective Estrogen Receptor Modulators
;
Vitamin D
;
Denosumab
8.Response: The Effects of Combined Treatment of Alendronate Plus Active or Plain Vitamin D on the Vitamin D Metabolism and Bone Turnover Marker in Patients with Osteoporosis (Endocrinol Metab 25:305-309, 2010, Jee-Hoon Koo et al.).
Endocrinology and Metabolism 2011;26(1):108-108
No abstract available.
Alendronate
;
Humans
;
Osteoporosis
;
Vitamin D
;
Vitamins
Result Analysis
Print
Save
E-mail